🚀 VC round data is live in beta, check it out!
Peptron Valuation Multiples
Discover revenue and EBITDA valuation multiples for Peptron and similar public comparables like Bayer SA, InnoCare Pharma, Shijiazhuang Yiling, Viking Therapeutics and more.
Peptron Overview
About Peptron
Peptron Inc is a biotechnology company engaged in developing fundamental technologies for peptide-based medicines. Its technology includes PeptrEX and SmartDepot. PeptrEX is an automatic system, enabling to synthesize simultaneously from a few to hundred types of peptides. SmartDepot is a proprietary ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of the drug. The group’s research and development products include Luphere Depot for the treatment of prostate cancer and endometriosis, SR Exenatide PT302 AND SR EXENATIDE PT304 for the treatment of type II diabetes, SR Exenatide PT320 and 330 for the treatment of Parkinson’s and Alzheimer’s disease and SR Octreotide for the treatment of acromegaly and carcinoid tumor.
Founded
1997
HQ
Employees
N/A
Website
Sectors
Financials (FY)
EV
$4B
Peptron Financials
Peptron reported last fiscal year revenue of $4M and negative EBITDA of ($7M).
In the same fiscal year, Peptron generated $1M in gross profit, ($7M) in EBITDA losses, and had net loss of ($9M).
Peptron P&L
In the most recent fiscal year, Peptron reported revenue of $4M and EBITDA of ($7M).
Peptron expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $4M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $1M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 27% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($7M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (183%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (377%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($9M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (245%) | XXX | XXX | XXX |
| Net Debt | — | — | $17M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Peptron Stock Performance
Peptron has current market cap of $4B, and enterprise value of $4B.
Market Cap Evolution
Peptron's stock price is $178.63.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4B | $4B | -1.7% | XXX | XXX | XXX | $-0.40 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPeptron Valuation Multiples
Peptron trades at 1075.3x EV/Revenue multiple, and (588.8x) EV/EBITDA.
Peptron Financial Valuation Multiples
As of April 19, 2026, Peptron has market cap of $4B and EV of $4B.
Equity research analysts estimate Peptron's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Peptron has a P/E ratio of (443.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 1075.3x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (588.8x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (285.0x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 3956.1x | XXX | XXX | XXX |
| P/E | — | XXX | (443.9x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (256.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Peptron Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Peptron Margins & Growth Rates
Peptron's revenue in the last fiscal year grew by 79%.
Peptron Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 79% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (183%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (44%) | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 25% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 43% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 274% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 404% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Peptron Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Peptron | XXX | XXX | XXX | XXX | XXX | XXX |
| Bayer SA | XXX | XXX | XXX | XXX | XXX | XXX |
| InnoCare Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Shijiazhuang Yiling | XXX | XXX | XXX | XXX | XXX | XXX |
| Viking Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Tianjin Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Peptron M&A Activity
Peptron acquired XXX companies to date.
Last acquisition by Peptron was on XXXXXXXX, XXXXX. Peptron acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Peptron
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPeptron Investment Activity
Peptron invested in XXX companies to date.
Peptron made its latest investment on XXXXXXXX, XXXXX. Peptron invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Peptron
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Peptron
| When was Peptron founded? | Peptron was founded in 1997. |
| Where is Peptron headquartered? | Peptron is headquartered in South Korea. |
| Who is the CEO of Peptron? | Peptron's CEO is Ho-Il Choi. |
| Is Peptron publicly listed? | Yes, Peptron is a public company listed on Korea Exchange. |
| What is the stock symbol of Peptron? | Peptron trades under 087010 ticker. |
| When did Peptron go public? | Peptron went public in 2015. |
| Who are competitors of Peptron? | Peptron main competitors are Bayer SA, InnoCare Pharma, Shijiazhuang Yiling, Viking Therapeutics. |
| What is the current market cap of Peptron? | Peptron's current market cap is $4B. |
| What is the current revenue of Peptron? | Peptron's last fiscal year revenue is $4M. |
| What is the current EV/Revenue multiple of Peptron? | Current revenue multiple of Peptron is 1075.3x. |
| Is Peptron profitable? | No, Peptron is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.